TWI613202B - 抗病毒化合物 - Google Patents
抗病毒化合物 Download PDFInfo
- Publication number
- TWI613202B TWI613202B TW102147531A TW102147531A TWI613202B TW I613202 B TWI613202 B TW I613202B TW 102147531 A TW102147531 A TW 102147531A TW 102147531 A TW102147531 A TW 102147531A TW I613202 B TWI613202 B TW I613202B
- Authority
- TW
- Taiwan
- Prior art keywords
- imidazol
- methylpyrrolidin
- carboxylic acid
- compound
- piperan
- Prior art date
Links
- 0 CC(C)C(*1(C)C)=*C2=C1c(cc1[s]c3cc(C(*4C)=C*=C4NC)ccc3c1c1)c1S2=C Chemical compound CC(C)C(*1(C)C)=*C2=C1c(cc1[s]c3cc(C(*4C)=C*=C4NC)ccc3c1c1)c1S2=C 0.000 description 3
- AALJQXXBQKKIOX-SKFAOREZSA-N C[C@@H](CC[C@H]1c2ncc(-c(cc3COc4c5)ccc3-c4cc(cc3)c5c4c3nc([C@H](CC[C@@H]3C)N3C([C@H](C3C[C@@H](C)O[C@H](C)C3)NC(OC)=O)=O)[nH]4)[nH]2)N1C([C@H](C1C[C@@H](C)O[C@H](C)C1)NC(OC)=O)=O Chemical compound C[C@@H](CC[C@H]1c2ncc(-c(cc3COc4c5)ccc3-c4cc(cc3)c5c4c3nc([C@H](CC[C@@H]3C)N3C([C@H](C3C[C@@H](C)O[C@H](C)C3)NC(OC)=O)=O)[nH]4)[nH]2)N1C([C@H](C1C[C@@H](C)O[C@H](C)C1)NC(OC)=O)=O AALJQXXBQKKIOX-SKFAOREZSA-N 0.000 description 3
- MQLNQYVZVZHRDH-UHFFFAOYSA-N CC(C)C1COCCC1 Chemical compound CC(C)C1COCCC1 MQLNQYVZVZHRDH-UHFFFAOYSA-N 0.000 description 2
- NBRBXGKOEOGLOI-UHFFFAOYSA-N CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(-c(ccc2c3)cc2ccc3NS(C)(=O)=O)c1OC Chemical compound CC(C)(C)c1cc(N(C=CC(N2)=O)C2=O)cc(-c(ccc2c3)cc2ccc3NS(C)(=O)=O)c1OC NBRBXGKOEOGLOI-UHFFFAOYSA-N 0.000 description 1
- FKHGWGULVDKLSF-UHFFFAOYSA-N CC(C)C(C)OC(F)F Chemical compound CC(C)C(C)OC(F)F FKHGWGULVDKLSF-UHFFFAOYSA-N 0.000 description 1
- FHCUMDQMBHQXKK-CDIODLITSA-N CC(C)[C@@H](C(N([C@@H](C)CC1)[C@@H]1c1nc(ccc2c3cc4OCc(cc(cc5)-c6cnc([C@H](C[C@H](COC)C7)N7C([C@@H](c7ccccc7)NC(OC)=O)=O)[nH]6)c5-c4c2)c3[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N([C@@H](C)CC1)[C@@H]1c1nc(ccc2c3cc4OCc(cc(cc5)-c6cnc([C@H](C[C@H](COC)C7)N7C([C@@H](c7ccccc7)NC(OC)=O)=O)[nH]6)c5-c4c2)c3[nH]1)=O)NC(OC)=O FHCUMDQMBHQXKK-CDIODLITSA-N 0.000 description 1
- QZZXPFOQOOOPMF-LRQMNSDQSA-N CC(C)[C@@H](C(N([C@@H](C)CC1)[C@@H]1c1ncc(-c(cc2)cc3c2-c2cc4ccc5nc([C@H](CCC6)N6C([C@H](C6C[C@@H](C)O[C@H](C)C6)NC(OC)=O)=O)[nH]c5c4cc2OC3)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N([C@@H](C)CC1)[C@@H]1c1ncc(-c(cc2)cc3c2-c2cc4ccc5nc([C@H](CCC6)N6C([C@H](C6C[C@@H](C)O[C@H](C)C6)NC(OC)=O)=O)[nH]c5c4cc2OC3)[nH]1)=O)NC(OC)=O QZZXPFOQOOOPMF-LRQMNSDQSA-N 0.000 description 1
- SGLCQZLDSXLCHR-QTTBUYDXSA-N CC(C)[C@@H](C(N([C@@H](C)CC1)[C@@H]1c1ncc(-c2ccc3-c4cc5ccc6nc([C@H](CC[C@@H]7C)N7C([C@@H](C7C[C@@H](C)O[C@H](C)C7)NC(OC)=O)=O)[nH]c6c5cc4OCc3c2)[nH]1)=O)NC(OC)=O Chemical compound CC(C)[C@@H](C(N([C@@H](C)CC1)[C@@H]1c1ncc(-c2ccc3-c4cc5ccc6nc([C@H](CC[C@@H]7C)N7C([C@@H](C7C[C@@H](C)O[C@H](C)C7)NC(OC)=O)=O)[nH]c6c5cc4OCc3c2)[nH]1)=O)NC(OC)=O SGLCQZLDSXLCHR-QTTBUYDXSA-N 0.000 description 1
- ZJNHYEYVBQDDRU-NWPUHYOBSA-N CC[C@H](CC1)[C@@H](C(N[C@](C2)([C@@H]2C(F)F)C(NS(C2(C)CC2)(=O)=O)=O)=O)N1C([C@H](C(C)C)NC(OC1[C@H](CCCCC(c2nc(ccc(OC)c3)c3nc2O)(F)F)C1)=O)=O Chemical compound CC[C@H](CC1)[C@@H](C(N[C@](C2)([C@@H]2C(F)F)C(NS(C2(C)CC2)(=O)=O)=O)=O)N1C([C@H](C(C)C)NC(OC1[C@H](CCCCC(c2nc(ccc(OC)c3)c3nc2O)(F)F)C1)=O)=O ZJNHYEYVBQDDRU-NWPUHYOBSA-N 0.000 description 1
- VURIQPIJYAFXQS-SALSSOGBSA-N C[C@@H](C[C@H]1c2ncc(-c(cc3COc4c5)ccc3-c4cc(cc3)c5c4c3nc(C(C[C@H](C)[C@@H]3C)N3C([C@H](C3C[C@@H](C)O[C@H](C)C3)NC(OC)=O)=O)[nH]4)[nH]2)[C@H](C)N1C([C@H](C1C[C@@H](C)O[C@H](C)C1)NC([O-]C)=O)=O Chemical compound C[C@@H](C[C@H]1c2ncc(-c(cc3COc4c5)ccc3-c4cc(cc3)c5c4c3nc(C(C[C@H](C)[C@@H]3C)N3C([C@H](C3C[C@@H](C)O[C@H](C)C3)NC(OC)=O)=O)[nH]4)[nH]2)[C@H](C)N1C([C@H](C1C[C@@H](C)O[C@H](C)C1)NC([O-]C)=O)=O VURIQPIJYAFXQS-SALSSOGBSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745452P | 2012-12-21 | 2012-12-21 | |
| US61/745,452 | 2012-12-21 | ||
| US13/830,346 | 2013-03-14 | ||
| US13/830,346 US9233974B2 (en) | 2012-12-21 | 2013-03-14 | Antiviral compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201441229A TW201441229A (zh) | 2014-11-01 |
| TWI613202B true TWI613202B (zh) | 2018-02-01 |
Family
ID=50974893
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW102147531A TWI613202B (zh) | 2012-12-21 | 2013-12-20 | 抗病毒化合物 |
| TW106146566A TW201835087A (zh) | 2012-12-21 | 2013-12-20 | 抗病毒化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW106146566A TW201835087A (zh) | 2012-12-21 | 2013-12-20 | 抗病毒化合物 |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US9233974B2 (enExample) |
| EP (3) | EP3239152A1 (enExample) |
| JP (1) | JP6333849B2 (enExample) |
| KR (2) | KR20200118903A (enExample) |
| CN (2) | CN107011350A (enExample) |
| AP (1) | AP2015008511A0 (enExample) |
| AR (1) | AR094262A1 (enExample) |
| AU (1) | AU2013361195B2 (enExample) |
| BR (1) | BR112015014333A8 (enExample) |
| CA (1) | CA2893963C (enExample) |
| CL (1) | CL2015001702A1 (enExample) |
| CR (1) | CR20150370A (enExample) |
| EA (2) | EA201790781A3 (enExample) |
| ES (1) | ES2626392T3 (enExample) |
| HK (2) | HK1214594A1 (enExample) |
| IL (1) | IL239496A0 (enExample) |
| MA (1) | MA38261A1 (enExample) |
| MD (1) | MD20150062A2 (enExample) |
| MX (1) | MX2015007888A (enExample) |
| PE (1) | PE20151423A1 (enExample) |
| PH (1) | PH12015501354A1 (enExample) |
| PL (1) | PL2935279T3 (enExample) |
| PT (1) | PT2935279T (enExample) |
| SG (1) | SG11201504746PA (enExample) |
| SI (1) | SI2935279T1 (enExample) |
| TW (2) | TWI613202B (enExample) |
| UY (1) | UY35241A (enExample) |
| WO (1) | WO2014100500A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012068234A2 (en) | 2010-11-17 | 2012-05-24 | Gilead Sciences, Inc. | Antiviral compounds |
| PT2907816T (pt) | 2011-11-16 | 2018-10-18 | Gilead Pharmasset Llc | Imidazolilimidazóis condensados como compostos antivirais |
| US20130309196A1 (en) * | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| GEP201706757B (en) | 2012-12-21 | 2017-10-25 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| US9398640B2 (en) | 2012-12-21 | 2016-07-19 | Halliburton Energy Services, Inc. | Digital multi-use thermo-cup |
| TWI627174B (zh) | 2013-03-14 | 2018-06-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調控劑 |
| US9040534B2 (en) | 2013-03-14 | 2015-05-26 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators |
| EP2970271B1 (en) | 2013-03-14 | 2017-11-08 | Janssen Pharmaceutica NV | P2x7 modulators |
| AU2014230814B2 (en) | 2013-03-14 | 2017-12-21 | Boehringer Ingelheim International Gmbh | Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C |
| TWI599567B (zh) | 2013-03-14 | 2017-09-21 | 健生藥品公司 | Ｐ２ｘ７調節劑 |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| CN105530933B (zh) | 2013-07-17 | 2018-12-11 | 百时美施贵宝公司 | 用于治疗hcv的包含联苯衍生物的组合产品 |
| JP2016529293A (ja) | 2013-08-27 | 2016-09-23 | ギリアド ファーマセット エルエルシー | ２つの抗ウイルス化合物の組合せ製剤 |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| AP2016009605A0 (en) | 2014-06-17 | 2016-12-31 | Pfizer | Substituted dihydroisoquinolinone compounds |
| WO2016039977A1 (en) | 2014-09-12 | 2016-03-17 | Janssen Pharmaceutica Nv | P2x7 modulators |
| JP6625616B2 (ja) | 2014-09-12 | 2019-12-25 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐ２ｘ７調節ｎ−アシル−トリアゾロピラジン |
| UA118610C2 (uk) | 2014-09-12 | 2019-02-11 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Спіроциклічні інгібітори катепсину c |
| IL296496B2 (en) | 2014-12-26 | 2024-10-01 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| CN110372559A (zh) * | 2014-12-29 | 2019-10-25 | 重庆博腾制药科技股份有限公司 | 一种(4S)-N-Boc-4--甲氧基甲基-L-脯氨酸的合成方法 |
| WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CN105732765B (zh) * | 2016-02-01 | 2019-07-26 | 杭州科巢生物科技有限公司 | 丙肝药物维帕他韦的新合成方法 |
| CN106916134B (zh) * | 2016-04-14 | 2020-04-17 | 苏州楚凯药业有限公司 | 一种10,11-二氢-5H-苯并[d]萘并[2,3-b]吡喃酮衍生物的制备方法 |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| EP4483875A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| MX2018014377A (es) | 2016-05-27 | 2019-03-14 | Gilead Sciences Inc | Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3). |
| CN106831737B (zh) * | 2017-02-27 | 2020-03-17 | 上海众强药业有限公司 | 维帕他韦及其衍生物的制备 |
| EP3641762B1 (en) | 2017-06-20 | 2026-02-18 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| AU2018335411B2 (en) * | 2017-09-21 | 2024-06-27 | Riboscience Llc | 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| TW202035409A (zh) | 2018-09-28 | 2020-10-01 | 比利時商健生藥品公司 | 單醯基甘油脂肪酶調節劑 |
| MY205440A (en) | 2018-09-28 | 2024-10-21 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
| AU2020358948A1 (en) | 2019-09-30 | 2022-05-26 | Janssen Pharmaceutica Nv | Radiolabelled MGL PET ligands |
| BR112022019077A2 (pt) | 2020-03-26 | 2022-12-27 | Janssen Pharmaceutica Nv | Moduladores da monoacilglicerol lipase |
| CA3219397A1 (en) | 2021-05-21 | 2022-11-24 | Gilead Sciences, Inc. | Tetracyclic compounds for the treatment of zika virus infection |
| JP7725617B2 (ja) * | 2021-05-21 | 2025-08-19 | ギリアード サイエンシーズ， インコーポレイテッド | ジカウイルス阻害剤としての五環式誘導体 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201240990A (en) * | 2010-11-17 | 2012-10-16 | Gilead Sciences Inc | Antiviral compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| EP0481214B1 (en) | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| DK1778702T3 (da) | 2004-07-16 | 2011-10-17 | Gilead Sciences Inc | Antivirale forbindelser |
| US7741347B2 (en) * | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2010096777A1 (en) * | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| US8552047B2 (en) * | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US20130309196A1 (en) * | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
-
2013
- 2013-03-14 US US13/830,346 patent/US9233974B2/en active Active
- 2013-12-19 CN CN201710186037.1A patent/CN107011350A/zh active Pending
- 2013-12-19 EP EP17160687.4A patent/EP3239152A1/en not_active Withdrawn
- 2013-12-19 ES ES13819144.0T patent/ES2626392T3/es active Active
- 2013-12-19 AU AU2013361195A patent/AU2013361195B2/en active Active
- 2013-12-19 PE PE2015001025A patent/PE20151423A1/es not_active Application Discontinuation
- 2013-12-19 SG SG11201504746PA patent/SG11201504746PA/en unknown
- 2013-12-19 EP EP18169933.1A patent/EP3404030A1/en not_active Withdrawn
- 2013-12-19 CA CA2893963A patent/CA2893963C/en active Active
- 2013-12-19 PT PT138191440T patent/PT2935279T/pt unknown
- 2013-12-19 PL PL13819144T patent/PL2935279T3/pl unknown
- 2013-12-19 EA EA201790781A patent/EA201790781A3/ru unknown
- 2013-12-19 EP EP13819144.0A patent/EP2935279B1/en active Active
- 2013-12-19 KR KR1020207028460A patent/KR20200118903A/ko not_active Ceased
- 2013-12-19 CN CN201380066203.4A patent/CN104918943B/zh active Active
- 2013-12-19 AP AP2015008511A patent/AP2015008511A0/xx unknown
- 2013-12-19 KR KR1020157018764A patent/KR102164390B1/ko active Active
- 2013-12-19 SI SI201330634A patent/SI2935279T1/sl unknown
- 2013-12-19 MA MA38261A patent/MA38261A1/fr unknown
- 2013-12-19 EA EA201590868A patent/EA027828B1/ru not_active IP Right Cessation
- 2013-12-19 MD MDA20150062A patent/MD20150062A2/ro not_active Application Discontinuation
- 2013-12-19 WO PCT/US2013/076734 patent/WO2014100500A1/en not_active Ceased
- 2013-12-19 BR BR112015014333A patent/BR112015014333A8/pt not_active Application Discontinuation
- 2013-12-19 JP JP2015549743A patent/JP6333849B2/ja active Active
- 2013-12-19 MX MX2015007888A patent/MX2015007888A/es unknown
- 2013-12-19 HK HK16102505.6A patent/HK1214594A1/zh unknown
- 2013-12-20 TW TW102147531A patent/TWI613202B/zh active
- 2013-12-20 UY UY0001035241A patent/UY35241A/es not_active Application Discontinuation
- 2013-12-20 AR ARP130105004A patent/AR094262A1/es unknown
- 2013-12-20 TW TW106146566A patent/TW201835087A/zh unknown
-
2015
- 2015-06-15 PH PH12015501354A patent/PH12015501354A1/en unknown
- 2015-06-17 CL CL2015001702A patent/CL2015001702A1/es unknown
- 2015-06-18 IL IL239496A patent/IL239496A0/en unknown
- 2015-07-10 CR CR20150370A patent/CR20150370A/es unknown
- 2015-12-03 US US14/957,988 patent/US20160083395A1/en not_active Abandoned
-
2016
- 2016-08-24 US US15/246,074 patent/US20160362416A1/en not_active Abandoned
-
2017
- 2017-08-16 US US15/679,014 patent/US20170369502A1/en not_active Abandoned
-
2018
- 2018-01-22 US US15/876,909 patent/US20180244684A1/en not_active Abandoned
- 2018-04-10 HK HK18104658.5A patent/HK1245263A1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201240990A (en) * | 2010-11-17 | 2012-10-16 | Gilead Sciences Inc | Antiviral compounds |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104918943B (zh) | 抗病毒化合物 | |
| KR101890400B1 (ko) | 항바이러스성 화합물로서의 축합된 이미다졸릴이미다졸 | |
| KR102078233B1 (ko) | 항바이러스성 화합물 | |
| AU2013262784A1 (en) | Antiviral compounds with an imidazole - biphenyl - imidazole core | |
| AU2015274863B2 (en) | Antiviral compounds | |
| HK1242304A1 (en) | Antiviral compounds | |
| HK1234741B (zh) | Hcv ns5a的抗病毒化合物抑制剂 | |
| HK1216177B (en) | Antiviral compounds | |
| OA17337A (en) | Antiviral compounds. | |
| HK1205126B (en) | Antiviral compounds inhibitors of hcv ns5b |